CDAK dividend history

– Reported positive initial data from exoSTING™ clinical trial; on track to provide data from all dose escalation cohorts in late 1H 2022 – – Investigational New Drug (IND) application cleared for exoASO™-STAT6, with clinical trial initiation expected 1H 2022 –                   – Initial safety, PK/PD and efficacy data for exoIL-12™ in CTCL patients anticipated late 1H 2022 – – Progressed preclinical pan-beta coronavirus vaccine program – CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today reported fourth quarte

– Announced strategic long-term exosome manufacturing collaboration with Lonza – – Initial data readout from exoSTING™ clinical trial expected in Q4 2021; initial data from exoIL-12™ trial in CTCL patients now anticipated in H1 2022 – – Investigational New Drug (IND) application filing for exoASO™-STAT6 expected in Q4 2021 – – Preclinical data showing new potential therapeutic applications for three engineered exosome candidates to be presented during SITC 2021 next week – CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new

– Initial safety and PK/PD data from Phase 1/2 study of exoSTING™ now expected in the fourth quarter of 2021 –            – Initial safety and efficacy data from Phase 1 trial of exoIL-12™ in CTCL anticipated by year-end – – IND filing for third clinical program, exoASO™-STAT6, planned for 2H 2021 – CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today reported second quarter 2021 financial results and operational progress. "We continue to be intensely focused on execution of our two lead clinical program

– Key clinical data from first in-human studies of engineered exosome therapeutic candidates, exoIL-12™ and exoSTING™, expected this year – – Data from multiple preclinical programs to be presented at ASGCT 2021 showing broad potential applications for engineered exosomes – CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today reported first quarter 2021 financial results and operational progress. "We are making excellent progress with our clinical and preclinical programs, which continue to generate furthe